POS1238 GLUCOCORTICOIDS, RITUXIMAB AND THE PRESENCE OF INTERSTITIAL LUNG DISEASE ARE ASSOCIATED WITH POOR OUTCOMES OF THE SARS-COV-2 INFECTION IN PATIENTS WITH RHEUMATOID ARTHRITIS: DATA FROM THE NATIONAL REGISTRY SAR-COVID.
Authors: A. B. Gómez Vara, T. Barbich, C. A. Isnardi, E. E. Schneeberger, G. Citera, V. V. Castro Coello, R. Baez, M. Haye, A. A. Reyes, J. A. Albiero, R. Tanten, E. Velozo, P. Alba, M. J. Gamba, C. G. Alonso, H. Maldonado Ficco, J. Gallino Yanzi, V. Savio, C. Asnal, C. Matellan, L. Takashima, L. Carlevaris, M. S. Gálvez Elkin, J. Scafati, M. García, N. German, M. L. Werner, C. Aeschlimann, S. E. Aguero, M. E. Calvo, L. Gonzalez Lucero, G. F. Rodriguez Gil, M. Mauri, S. Petruzzelli, D. Castrillon Bustamante, L. Ibañez Zurlo, D. Alonso, J. L. Tomas, D. L. Vasquez, S. Soares de Souza, N. Herscovich, L. Raiti, J. M. Mareco, D. Guaglianone, C. Ledesma, M. P. Diaz, M. E. Bedoya, B. Kisluk, G. Gómez, K. Roberts, R. Quintana, G. Pons-Estel
Journal: Annals of the Rheumatic Diseases (2022)

Background High disease activity, treatment with glucocorticoids (GC) and rituximab (RTX), have been related to worse outcomes of COVID-19. Objectives To assess the clinical characteristics and severity of the SARS-CoV-2 infection in patients with rheumatoid arthritis (RA) included in the SAR-COVID registry and to identify factors associated with poor outcomes. Methods SAR-COVID is a national, longitudinal and observational registry. Patients of ≥18 years old, with diagnosis of RA (ACR-EULAR criteria 2010) who had confirmed SARS-CoV-2 infection (RT-PCR or positive serology) were included between 13-8-20 and 31-7-21. Sociodemographic and clinical data, comorbidities, disease activity and treatment at the moment of the SARS-CoV-2 infection were collected. Additionally, infection symptoms, complications, medical interventions and treatments for COVID-19 were registered. Infection severity was assessed using the WHO-ordinal scale (WHO-OS) 1 . A cut-off value of ≥5 identified patients with severe COVID-19 and those who died. Statistical analysis : Descriptive statistics. Chi 2 or Fischer test, Student T test or Mann-Whitney and Kruskal Wallis or ANOVA, as appropriate. Multiple logistic regression model. Results A total of 801 patients were included, with a mean age of 53.1 ± 12.9 years, most of them were female (84.5%) and the median ( m ) disease duration was 8 years (IQR 4-14). One third were in remission and 46.4% had comorbidities, being the most frequent, hypertension (26.9 %), dyslipidemia (13.5 %), obesity (13.4 %) and diabetes (8.9%). Moreover, 3.2% had interstitial lung disease (ILD) associated with RA. At SARS-CoV-2 diagnosis, 42.5% were receiving glucocorticoids (GC), 73.9% conventional (c) disease modifying antirheumatic drugs (DMARD), 24% biologic (b) DMARD and 9.1% targeted synthetic (ts) DMARD. Among bDMARD, the most frequently used were TNF inhibitors (17%), followed by abatacept (2.8%), IL-6 inhibitors (2.4%) and rituximab (RTX) (2.1%). During the SARS-CoV-2 infection, 95.8% had symptoms, 27% required hospitalization, 7.9% presented complications and 4.4% died due to COVID-19. Severe disease and death (WHO-OS≥5) was present in 7.5% of the patients. They were older (62.9±12.5 vs 52.2±12.7, p&lt;0.001), and they had more frequently ILD (18.5% vs 2%, p&lt;0.001), comorbidities (82.5% vs 43.7%, p&lt;0.001), ≥2 comorbidities (60.3% vs 25.8%, p&lt;0.001), treatment with GC (61% vs 40.7%, p=0.04) and RTX (8.3% vs 1.6%, p=0.007). Conversely, the use of cDMARD and TNF inhibitors was more frequent in patients with WHO-OS&lt;5, nevertheless this difference was not significant. Disease activity was comparable between groups. In multivariable analysis, older age, the presence of diabetes, ILD, the use of GC and RTX were significantly associated with WHO-OS≥5 (Figure 1). Furthermore, older age (65.7±10.8 vs 52.4±12.8, p&lt;0.001), the presence of comorbidities (87.9% vs 44.7%, p&lt;0.001), chronic obstructive pulmonary disease (21.9% vs 5.2%, p=0.002), diabetes (30.3% vs 7.9%, p&lt;0.001), hypertension (57.6% vs 25.6%, p&lt;0.001), cardiovascular disease (15.6% vs 3.2%, p=0.005), cancer (9.1% vs 1.3%, p=0.001), ILD (23.3% vs 2.4%, p&lt;0.001) and the use of GC (61.8% vs 41.4%, p=0.02) were associated with mortality. Older age [OR 1.1 IC95% 1.06-1.13] and the use of GC 5-10 mg/day [OR 4.6 IC95% 1.8-11.6] remained significantly associated with death due to COVID-19. Figure 1. Factors associated with severe disease and death due to COVID-19 (WHO-OS≥5) in patients with rheumatoid arthritis. Multivariable analysis. (ref.: reference; PDN: prednisone; OR: odds ratio; CI: confidence interval) Conclusion Treatment with RTX and GC, as well as older age, the presence of diabetes and ILD were associated with poor COVID-19 outcomes in this national cohort of patients with RA. Older patients and those taking GC had a higher mortality rate. References [1]World Health Organization coronavirus disease (COVID-19) Therapeutic Trial Synopsis Draft 2020. Disclosure of Interests None declared